Lv1
100 积分 2024-09-11 加入
Abstract P5-07-28: The next-generation CDK4-selective inhibitor atirmociclib (PF-07220060) in combination with letrozole as first-line treatment in patients with HR+/HER2+ metastatic breast cancer
2天前
已关闭
520P Long-term safety and efficacy of first-line atirmociclib + letrozole for the treatment of patients with HR+/HER2− metastatic breast cancer (mBC)
3天前
已完结
Novel Therapeutics in Advanced Breast Cancer: A Review of Current Phase I Clinical Trials
4天前
已完结
618MO Phase Ib/II first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors
4天前
已关闭
皖公网安备34019202002308
